Chairpersons :

Avinash Deo, Vivek Agarwala, Amul Kapoor

Reviewer :

Chetan Deshmukh

1. A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the

presence of dual HER2-blockade for HER2+ breast cancer: The TRAIN-2 study (BOOG

2012-03)

Author: Mette S.

Citation: ASCO Abstract 507 Journal of Clinical Oncology 35, no. 15_suppl (May

2017) 507-507

2. Phase III study of Lapatinib (L) plus Trastuzumab (T) and Aromatase Inhibitor (AI) vs

T+AI vs L+AI in Postmenopausal Women (PMW) with HER2+, HR+ Metastatic Breast

Cancer (MBC): Alternative

Author: William John Gradishar

Citation: ASCO Abstract 1004 Journal of Clinical Oncology 35, no. 15_suppl (May 2017)

1004-1004

3. Phase III, randomized study of first-line trastuzumab emtansine (T-DM1) ± Pertuzumab

(P) vs. Trastuzumab + Taxane (HT) treatment of HER2-positive MBC: Final Overall

Survival (OS) and safety from MARIANNE

Author: Edith A. Perez

Citation: ASCO ABSTRACT 1003 Journal of Clinical Oncology 35, no. 15_suppl (May

2017) 1003-1003